A thorough men's panel typically covers total and free testosterone, SHBG, LH, FSH, estradiol, prolactin, a CBC, a comprehensive metabolic panel, a lipid panel, HbA1c, PSA (age-appropriate), and vitamin D. Each marker clarifies a different question: gonadal signal, metabolic risk, prostate baseline, or a confounder worth ruling out before any protocol.
A testosterone number in isolation is a trivia fact. The same 420 ng/dL means something very different in a 32-year-old with low libido and an SHBG of 65 than it does in a 55-year-old with central adiposity, an HbA1c of 6.1%, and an SHBG of 18. That's why a men's health panel isn't one test — it's a group of markers chosen so each one answers a specific clinical question the others can't.
Here's what a thorough draw typically includes, and why each line is on it.
Total testosterone — the headline number
Total testosterone is the starting point, but it's a screening tool, not a diagnosis. The Endocrine Society recommends confirming a low value with a second morning (ideally fasting) measurement, because levels fluctuate diurnally and day-to-day, and a single low draw misclassifies a meaningful share of men.
Harmonized reference data from four large cohorts put the middle tertile for healthy, non-obese young men roughly in the 264–916 ng/dL range, which is where most modern lab reference intervals come from. Where you fall in that range only becomes actionable once the rest of the panel is on the page.
Free testosterone and SHBG — what's actually bioavailable
Sex hormone-binding globulin (SHBG) determines how much of your total testosterone is bound up and inactive versus free and able to act on tissue. SHBG goes up with age, hyperthyroidism, and liver disease; it drops with insulin resistance, obesity, and nephrotic syndrome.
That means two men with identical total T can have very different free T — and very different symptoms. Guidelines recommend calculating or measuring free testosterone (equilibrium dialysis is the reference method) when total T is borderline or when SHBG is likely to be abnormal, which is most of the men who actually show up with symptoms.
LH and FSH — where the problem is
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) tell you whether a low testosterone is primary (testicular) or secondary (pituitary/hypothalamic). High LH with low T points at the testes. Low or inappropriately normal LH with low T points upstream, which changes the workup — prolactin, iron studies, pituitary imaging in the right context — and changes the conversation about fertility-preserving options versus traditional testosterone replacement.
Estradiol — the other half of the axis
Estradiol in men is not a bug; it's load-bearing for bone, libido, mood, and cardiovascular health. It's also downstream of testosterone via aromatase, so it rises with higher T, higher body fat, and some medications.
A sensitive (LC-MS/MS) estradiol assay is the one worth ordering — the older immunoassays are unreliable at male concentrations. Baseline E2 matters because the first question on therapy isn't "is it high," it's "did it change in a way that tracks with symptoms."
Prolactin — the quiet confounder
Prolactin isn't glamorous, but an elevated level can suppress the HPG axis and present as low libido with low or low-normal testosterone — which looks like hypogonadism until you check. The AUA guideline includes prolactin in the workup for men with unexplained secondary hypogonadism, and it's cheap insurance against missing a prolactinoma.
The point of the panelA men's panel exists so a clinician can tell whether your testosterone number is the problem, the symptom, or a red herring — and that decision requires the other markers on the page.
CBC — the TRT safety marker
A complete blood count gives you hematocrit and hemoglobin, which matter because testosterone therapy predictably raises red cell mass. Erythrocytosis is the most common dose-limiting side effect of TRT, and guideline-recommended monitoring exists specifically because of it. Having a baseline before any protocol starts is what makes the follow-up value interpretable.
Comprehensive metabolic panel — liver, kidneys, electrolytes
The CMP covers liver enzymes, kidney function (creatinine, eGFR), glucose, and electrolytes. Liver and kidney status affect how medications are chosen and dosed, and abnormalities here reshape the plan more often than people expect. Fasting glucose from this panel also pairs with HbA1c for a fuller metabolic picture.
HbA1c and fasting glucose — the metabolic context
Metabolic health and testosterone are reciprocally entangled: insulin resistance lowers SHBG and total testosterone, and low testosterone is associated with worsened insulin sensitivity. An HbA1c in the prediabetes range (5.7–6.4% per ADA criteria) changes both the differential and the plan — treating only the hormone and ignoring the metabolism is a short-term win at best.
Lipid panel — baseline cardiovascular risk
Standard lipids — total cholesterol, LDL-C, HDL-C, triglycerides — anchor cardiovascular risk estimation per the AHA/ACC cholesterol guideline. For men considering any hormonal protocol, this is the baseline against which later changes get measured, and it's often the finding that drives the biggest health improvement regardless of what happens with testosterone.
PSA — age-appropriate prostate baseline
Prostate-specific antigen is included for men in the age range where screening is a shared decision — the AUA/SUO 2023 guideline frames routine PSA screening as a conversation starting around age 45–50 for average-risk men, earlier for higher-risk groups. A baseline PSA before testosterone therapy is standard of care, with follow-up at defined intervals, because clinicians want to see the trajectory, not just the number.
Vitamin D, ferritin, TSH — the common confounders
Low vitamin D, iron deficiency, and thyroid dysfunction all produce fatigue, low libido, mood changes, and poor exercise tolerance — the same symptoms that drive men to ask about testosterone in the first place. Checking them up front avoids treating the wrong axis.
The best panel isn't the biggest panel — it's the one where every marker answers a question a clinician would otherwise have to guess at.
How this fits a real workup
If you choose to do bloodwork through us, these are the markers worth having on the first draw, because they let a clinician separate a hormone problem from a metabolic problem from a confounder. Not every man needs every marker on every follow-up — monitoring panels are narrower and target the specific things a given protocol can move.
The honest version is this: a number without context is a guess with extra steps. The panel exists to turn a guess into a plan tuned to your numbers.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Source
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. Source
- Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline. J Urol. 2023;210(1):46-53. Source
- American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. Source
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. Source
- Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173. Source
Real labs. Plain-English plan.
A clinician-ordered, 80+ biomarker panel. Results in 3–5 days, with a personalized roadmap from a US-licensed clinician — not a chart you have to decode yourself.
See my numbers →Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.
